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Abstract
Background: Lenvatinib is a multikinase inhibitor approved to treat radioiodinerefractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This
study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day would
provide comparable efficacy with reduced toxicity.
Methods: Patients with RR-DTC were randomized to lenvatinib 24 mg/day or 18 mg/day.
The primary efficacy endpoint was objective response rate as of week 24 (ORRwk24); the
odds ratio noninferiority margin was 0.4. The primary safety endpoint was frequency
of grade ≥3 treatment-emergent adverse events (TEAEs) as of week 24. Tumors were
assessed using RECIST v1.1. TEAEs were monitored and recorded.
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Thyroid cancer is estimated to have a worldwide incidence
of approximately 567 000 cases (1), and differentiated thyroid cancer (DTC) makes up about 95% of these cases (2).
DTC is typically associated with a good prognosis, and
approximately 85% of patients are cured following some
combination of surgery, radioiodine therapy, and thyroidstimulating hormone suppression (3-6). However, the remaining patients with radioiodine refractory (RR)-DTC
have a 5-year survival rate of as low as 10% (4).
Inhibition of tumor cell growth pathways through the
use of tyrosine kinase inhibitors has led to their application
in the treatment of RR-DTC (2). Specifically, sorafenib was
approved for the treatment of RR-DTC based on the pivotal DECISION trial, where median progression-free survival (PFS) was 5.8 months in patients treated with placebo
vs 10.8 months in patients treated with sorafenib; the objective response rate (ORR) for sorafenib was 12.2% (7).
Lenvatinib, a multikinase inhibitor (8-11), was approved
for the treatment of patients with locally recurrent or metastatic progressive RR-DTC based on the global Phase 3
SELECT study, in which median PFS was 3.6 months in
patients treated with placebo vs 18.3 months in patients
treated with lenvatinib; the ORR for lenvatinib was 64.8%
(12,13). However, 82.4% of patients in the lenvatinib arm
had a dose interruption, and 67.8% of patients had a dose
reduction due to an adverse event (AE), leading to a mean
lenvatinib dose of 17.2 mg/day (12). AEs led to the discontinuation of lenvatinib in 14.2% of patients.
Since the approval of lenvatinib, the authors have noted
that some physicians prefer starting patients at a lower
dose out of concern that AEs will be encountered (14,15).
Moreover, regulatory concerns arose regarding whether a
lower dose of lenvatinib would provide comparable efficacy
but improved safety relative to the approved 24-mg/day
starting dose in patients with RR-DTC. Therefore, this study
sought to assess the safety and efficacy of a starting dose
of lenvatinib 18 mg/day (LEN18) vs lenvatinib 24 mg/day

(LEN24). To control for provider and patient bias, the assigned lenvatinib dose was given in a double-blinded fashion.

Methods
Study Design
This multicenter, randomized, double-blind, Phase 2 study
compared the safety and efficacy of LEN18 with LEN24 in
28-day cycles in patients with RR-DTC (NCT02702388).
The study was initially designed with 3 lenvatinib dosing
arms, utilizing starting doses of 14 mg/day, 20 mg/day, and
24 mg/day. However, this was subsequently revised to a
2-arm study design based on the results of a population
pharmacokinetics/pharmacodynamics modeling analysis,
which was conducted with 7 dosing regimens, some of
which included uptitration to 24 mg (16). The modeling
analysis used simulated tumor-size profiles to determine
that LEN24 predicted a derived ORR as of 24 weeks
(ORRwk24) of 50.0%, while LEN18 could potentially provide an ORRwk24 of 41.5% with an improved safety profile
(ie, a reduction in the number of patients who required a
dose reduction due to an AE). These data indicated that
the 14-mg/day starting dose was unlikely to provide comparable efficacy to, and the 20 mg/day starting dose would
not be distinguishable from, LEN24 (16), and therefore the
study design was revised (as of February 13, 2017). The 41
patients who had been randomly assigned to those dose
groups were unblinded shortly after enrollment, transitioned off the study, and are not included in this analysis.
Randomization and masking were performed centrally by an interactive voice and web response system.
Patients were randomly assigned 1:1 to the LEN24 arm or
the LEN18 arm and were stratified by age (≤65 years or
>65 years) and Eastern Cooperative Oncology Group performance status (ECOG PS; 0 vs 1 or 2). Dosing was blinded
so that all patients received their dose as a combination of
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Results: The ORRwk24 was 57.3% (95% CI 46.1, 68.5) in the lenvatinib 24-mg arm and 40.3%
(95% CI 29.3, 51.2) in the lenvatinib 18-mg arm, with an odds ratio (18/24 mg) of 0.50 (95%
CI 0.26, 0.96). As of week 24, the rates of TEAEs grade ≥3 were 61.3% in the lenvatinib
24-mg arm and 57.1% in the lenvatinib 18-mg arm, a difference of −4.2% (95% CI −19.8,
11.4).
Conclusion: A starting dose of lenvatinib 18 mg/day did not demonstrate noninferiority
compared to a starting dose of 24 mg/day as assessed by ORRwk24 in patients with RR-DTC.
The results represent a clinically meaningful difference in ORRwk24. The safety profile was
comparable, with no clinically relevant difference between arms. These results support
the continued use of the approved starting dose of lenvatinib 24 mg/day in patients with
RR-DTC and adjusting the dose as necessary.
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Patients
Eligible patients were ≥18 years of age, had an ECOG PS
of ≤2, 1 or no prior vascular endothelial growth factor
(VEGF)/VEGF receptor–targeted therapy, adequate organ
function, and a histologically or cytologically confirmed
diagnosis of RR-DTC, with both evidence of disease progression within 13 months before providing informed
consent and measurable disease assessed by Response
Evaluation Criteria In Solid Tumors version 1.1 (RECIST
v1.1) confirmed by central radiographic review. A complete
list of the inclusion and exclusion criteria can be found in
the trial listing on www.clinicaltrials.gov (NCT02702388).
Written informed consent was provided by all patients
before undergoing any study-specific procedures. These
practices were designed to ensure adherence to Good
Clinical Practice Guidelines and the principles of the World
Medical Association Declaration of Helsinki.

Study Endpoints
The primary efficacy endpoint was ORRwk24, and the
primary safety endpoint was treatment-emergent AEs
(TEAEs) of grade ≥3 in the first 24 weeks after randomization. ORRwk24 was selected as the primary endpoint because it better predicts PFS and allows a sample size and
study duration with a defined cutoff not constrained by
accumulation of events. SELECT data showed that pronounced tumor responses to lenvatinib in patients with
RR-DTC typically occur within 8 weeks (17). Specifically,
the median time to first objective response was 2.0 months
(95% CI 1.9, 3.5), and a rapid initial decline in tumor size
(median decrease of 25%) was seen by the time of the first
radiological tumor assessment at 8 weeks. Key secondary
endpoints of this study included PFS, safety, and tolerability. Exploratory endpoints included overall survival
(OS). Tumor responses were assessed by investigator per
RECIST v1.1. All AEs were recorded and were reported
using Common Terminology Criteria for Adverse Events
(v4.03) grades.

Statistics
Efficacy analyses were conducted using the full analysis
set, which included all randomly assigned patients. The
noninferiority analysis comparing ORRwk24 between the
LEN24 and LEN18 arms was performed with a 1-sided
alpha of 0.025, based on the calculated odds ratio of
ORRwk24 response (18 mg vs 24 mg) along with its 95% CI
using the Cochran-Mantel-Haenszel method, stratified by
the randomization stratification factors. The test was performed per the 95% CI using the noninferiority margin of
0.4. Overall ORR was analyzed as a sensitivity analysis according to the same approach for ORRwk24. The odds ratio
and 95% CIs between treatment groups were further analyzed in forest plots by subgroups defined by the randomization stratification factors: age (≤65 vs >65 years) and
ECOG PS (0 vs 1 or 2). Additional subgroups included sex,
race, prior VEGF-targeted therapy (0 vs 1), region, histology, baseline thyroid-stimulating hormone level, baseline
weight group (≤60 vs >60 kg), prior anticancer radiotherapy (yes vs no), and prior anticancer medication (yes
vs no).
A best overall response of stable disease was required
to be at least 7 weeks following randomization. Durable
stable disease was defined as the duration of stable disease ≥23 weeks after randomization. Disease control rate
(defined as stable disease + complete response + partial response), and clinical benefit rate (defined as complete response + partial response + durable stable disease), and
the corresponding 2-sided 95% CIs were calculated by
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4 capsules irrespective of their dose. Randomization data
were kept strictly confidential, filed securely by an appropriate group with the sponsor, and accessible only to authorized persons (eg, Eisai Global Safety) until the time
of unblinding, per standard operating procedure. Patients
who experienced toxicities underwent dose interruptions
and dose adjustments based on the grade of the toxicity.
Dose reductions were performed in a blinded fashion per
physician direction.
Patients received treatment, in a double-blinded fashion,
until disease progression, development of unacceptable
toxicity, request to discontinue, withdrawal of consent, or
loss to follow-up. Upon disease progression, patients were
followed for survival and PFS after the next line of treatment until data cutoff for the primary analysis, which occurred when the final patient enrolled had completed the
week-24 tumor assessment.
The randomization phase of this study consisted of
the treatment period and the follow-up period. During
the treatment period, patients received lenvatinib orally at a starting dose of 24 mg/day or 18 mg/day.
Dose modification for AEs for all patients followed
the study protocol. Dose-reduction steps for patients
in the LEN24 arm were 20 mg, 14 mg, 10 mg, and
8 mg per day. In the LEN18 arm, dose reductions were
performed to 14 mg, 10 mg, 8 mg, and 4 mg per day.
The follow-up period began immediately after the offtreatment visit and continued until patient death, withdrawal of consent, or the data cutoff for the primary
analysis. Patients were followed every 12 weeks (±1
week) during the follow-up period and monitored for
survival, PFS after the next line of treatment, and all
anticancer treatments received.
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Results
Patient Disposition and Baseline Characteristics
Patient baseline characteristics are shown in Table 1. Of
the 152 patients, 75 were randomly assigned to the LEN24
arm, and 77 were randomly assigned to the LEN18 arm.
The overall median age was 65.5 years (range 21-92 years).

ECOG PS was generally similar between the arms, whereas
more patients in the LEN18 arm (n = 25, 32.5%) had received prior VEGF-targeted therapy vs patients in the
LEN24 arm (n = 14, 18.7%).
At the data cutoff date (December 12, 2019), 43 patients
(57.3%) in the LEN24 arm and 35 patients (45.5%) in the
LEN18 arm had treatment ongoing; 13 patients (17.3%) in
the LEN24 arm and 20 patients (26.0%) in the LEN18 arm
had discontinued the study drug because of disease progression (Fig. 1). Equal numbers of patients in both arms discontinued treatment due to withdrawal of consent (n = 2,
each arm) or patient choice (n = 5, each arm) (Fig. 1).

Efficacy
As of week 24, patients in the LEN24 arm had an ORR
of 57.3% (95% CI 46.1, 68.5) compared to an ORR of
40.3% (95% CI 29.3, 51.2) in the LEN18 arm (Table 2).
The difference between treatment arms, using the LEN24
arm as the control, was −17.1% (95% CI −32.7, −1.4) with
an odds ratio of 0.50 (95% CI 0.26, 0.96). The lower limit
of the CI of the odds ratio was lower than the predefined
noninferiority margin of 0.4; therefore, noninferiority of
LEN18 compared to LEN24 was not met. Overall ORR
was similar to ORRwk24 for both groups (Table 2).
Among patients with an objective response, median duration of response was not reached [95% CI 18.4, not estimable (NE)] in the LEN24 arm (n = 48) and 20.8 months
(95% CI 15.1, NE) in the LEN18 arm (n = 36). The disease
control rate was 93.3% in the LEN24 arm and 87.0% in
the LEN18 arm. ORRwk24 and overall ORR according to
baseline characteristics are shown in Figure 2. Subgroup
analyses of ORR favored (numerically) the LEN24 arm regardless of exposure to prior VEGF-targeted therapy as of
week 24 (Fig. 2A) and overall (Fig. 2B).
Median PFS was not reached in the LEN24 arm (95% CI
22.1, NE) and was 24.4 months in the LEN18 arm (95%
CI 14.7, NE) (Fig. 3). Median duration of follow-up for PFS
was 12.8 months (95% CI 10.8, 15.3) in the LEN24 arm
and 11.2 months (95% CI 7.5, 14.6) in the LEN18 arm.
Most patients experienced a decrease in size of target lesions
(Fig. 4). Median OS was not reached in either treatment
arm. At 12 months, the OS rate was 90.0% (95% CI 80.0,
95.1) in the LEN24 arm and 86.5% (95% CI 75.3, 92.8) in
the LEN18 arm. Median duration of follow-up for OS was
15.5 months (95% CI 13.0, 19.4) in the LEN24 arm and
14.6 months (95% CI 12.2, 17.6) in the LEN18 arm.

Safety
The primary safety endpoint demonstrated that, as of week
24, incidences of grade ≥3 severity TEAEs were similar
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treatment group. Treatment differences (percentage-point
difference) for the LEN24 vs LEN18 arms were summarized along with the corresponding 95% CIs based on the
normal approximation.
Duration of response was defined for responders as the
time from the date of first documented response until date
of documented progression or death in the absence of disease progression, with the end of response coinciding with
the date of progression or death from any cause used for
the PFS endpoint. Duration of response was censored at
28 days after treatment end date. The time to first objective
response was defined as the time from randomization to
the first documentation of a response of partial response
or complete response. Medians of duration of response and
time to response were summarized using Kaplan-Meier
product-limit estimates for each treatment group and were
presented with 2-sided 95% CIs.
PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or date of death, whichever occurred first. Patients
were censored 28 days after treatment end date. The
stratified log-rank test, using ECOG PS and age group as
strata, was used to compare differences in PFS as assessed
by investigator between the LEN24 and LEN18 arms. The
hazard ratios and 95% CIs for the treatment comparisons
were estimated by stratified Cox regression including treatment as a factor and ECOG PS and age group as strata.
The Kaplan-Meier product-limit estimate for each treatment group was reported and plotted over time. OS was
analyzed in a similar manner to PFS.
All safety analyses were performed on the safety analysis set, which included all patients who were randomly
assigned and received at least 1 dose of study drug. For
the analysis of the primary safety endpoint, the frequency
(number and percentage) of TEAEs with Common
Terminology Criteria for Adverse Events (v4.03) grade ≥3
were summarized by treatment group; the difference in
the percentage between the treatment arms was presented
with a 95% CI using asymptotic normal approximation.
AEs and serious AEs, laboratory test results, other safety
assessments, and their changes from baseline were summarized using descriptive statistics. Time to treatment
discontinuation because of an AE, number of dose reductions, and time to first dose reduction were summarized.
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Table 1. Demographic and other baseline characteristics
Parameter
24 mg
(n = 75)

18 mg
(n = 77)

65.0
(36-92)
41 (54.7)

66.0
(21-89)
37 (48.1)

44 (58.7)
31 (41.3)
0
69 (92.0)

45 (58.4)
29 (37.7)
3 (3.9)
71 (92.2)

15 (20.0)
36 (48.0)
24 (32.0)

27 (35.1)
33 (42.9)
17 (22.1)

63 (84.0)
12 (16.0)
1 (1.3)
74 (98.7)

58 (75.3)
19 (24.7)
0
77 (100)

61 (81.3)
14 (18.7)
11 (14.7)
0
2 (2.7)
1 (1.3)

52 (67.5)
25 (32.5)
13 (16.9)
7 (9.1)
2 (2.6)
1 (1.3)

21 (28.0)
22 (29.3)
74 (98.7)
75 (100)

28 (36.4)
35 (45.5)
75 (97.4)
76 (98.7)

Abbreviations: 131I, radioiodine; DTC, differentiated thyroid cancer; ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid
Tumors; TSH, thyroid-stimulating hormone; VEGF, vascular endothelial growth factor.
a
Includes patients from Republic of Korea (n = 20) and Russian Federation (n = 21). Australia (n = 5) is included in North America.
b
VEGF-targeted therapies administered to ≥2 patients. Patients could be included in more than 1 category.
c
Includes but is not limited to VEGF-targeted therapy and cytotoxic chemotherapy. It does not include prior radioiodine therapy.
d
There were 3 patients in the study who apparently did not receive prior radioiodine therapy. In each of these patients, there was no uptake on 131I scan, but there
was disease progression by RECIST v1.1. These patients met the inclusion criterion “Subjects must be 131I-refractory/resistant as defined by at least 1 of the following: (a) one or more measurable lesions that does/do not demonstrate iodine uptake on any radioiodine scan.”
e
Includes thyroid adenoma removal, thyroid cystectomy, thyroid nodule removal, thyroid operation, and thyroidectomy.

between arms. There was a decreased incidence of grade
≥3 TEAEs of 4.2% (95% CI −19.8, 11.4) in the LEN18
arm (n = 44, 57.1%) compared to patients in the LEN24
arm (n = 46, 61.3%) (Table 3). The most common TEAEs
of grade ≥3 as of week 24 were (LEN24; LEN18) hypertension (n = 19, 25.3%; n = 15, 19.5%), proteinuria (n = 5,
6.7%; n = 4, 5.2%), and asthenia (n = 2, 2.7%; n = 4,
5.2%) (Table 3). The most common overall TEAEs are
listed in Table 4.
Among patients in the LEN24 and LEN18 arms, TEAEs
led to dose interruption in 48 (64.0%) and 51 (66.2%) patients, respectively; dose reduction in 52 (69.3%) and 46

(59.7%) patients, respectively; and treatment discontinuation in 11 (14.7%) and 13 (16.9%) patients, respectively.
The median time to first dose reduction (among all patients
including censors) was 15.3 weeks (95% CI 12.1, 20.1) in
the LEN24 arm and 24.1 weeks (95% CI 11.1, 35.9) in
the LEN18 arm. Treatment-related TEAEs that led to dose
modifications are shown in Table 3.
Overall, 9/152 (5.9%) patients experienced a fatal TEAE;
6/75 (8.0%) patients in the LEN24 arm and 3/77 (3.9%)
patients in the LEN18 arm (Table 3). Of these, 1 TEAE was
considered possibly related to study treatment by the investigator (sudden death of unknown cause in the LEN24 arm).
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Median age, years
Range
Sex, male, n (%)
ECOG performance status, n (%)
0
1
2
TSH ≤ 0.5 (µIU/mL), n (%)
Geographic region, n (%)
Europe
North America
Othera
DTC subtype, n (%)
Papillary
Follicular
Locally advanced DTC, n (%)
Metastatic DTC, n (%)
Prior VEGF-targeted therapies, n (%)
0
1
  Sorafenibb
  Pazopanibb
  Cabozantinibb
  Vandetanibb
Prior therapy, n (%)
Anticancer medicationsc
Radiotherapy
Radioiodine therapyd
Antithyroid cancer surgerye

Lenvatinib starting dose/day
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Enrolled
N = 241
Failed screening
n = 89
Inclusion/exclusion criteria: n = 68
Adverse eventa: n = 2

Randomly assigned
n = 152

Lenvatinib 18 mg
n = 77

Treatment ongoing
n = 43 (57.3%)
Treatment
discontinued
n = 32 (42.7%)

Otherb: n = 10

Progressive disease:
n = 13 (17.3%)
Adverse event: n = 10 (13.3%)

Treatment ongoing
n = 35 (45.5%)
Treatment
discontinued
n = 42 (54.5%)

Progressive disease:
n = 20 (26.0%)
Adverse event: n = 12 (15.6%)

Withdrawal: n = 2 (2.7%)

Withdrawal: n = 2 (2.6%)

Patient choice: n = 5 (6.7%)

Patient choice: n = 5 (6.5%)

Otherc: n = 2 (2.7%)

Otherd: n = 3 (3.9%)

Figure 1. Patient enrollment, randomization, and treatment. aOf the 2 patients who failed screening due to an adverse event, both had serious adverse events requiring hospitalization (dyspnea and increasing cancer bone pain; pathologic femoral shaft fracture and a traumatic radius fracture).
b
Other reasons for failing screening were exceeding the screening window (n = 9) and patient decision (n = 1). cOther reasons for treatment discontinuation were clinical disease progression (n = 2). dOther reasons for treatment discontinuation were clinical disease progression (n = 1), sponsor
decision (n = 1), and prohibited anticancer treatment (n = 1).

The other fatalities were ascribed to disease progression and
TEAEs deemed not related to lenvatinib treatment (subcutaneous emphysema, septic shock, and malignant pleural
effusion).

Treatment Exposure
The median overall daily dose intensity per patient was
18.7 mg/day for patients in the LEN24 arm and 15.4 mg/
day for patients in the LEN18 arm. The number of patientmonths for patients in the LEN24 and LEN18 arms were
928.2 and 792.9, respectively. The maximum durations
of dose interruptions were generally similar between the
dosing arms (Table 5).

Discussion
Lenvatinib has previously demonstrated efficacy in the
treatment of patients with RR-DTC (12) and is approved
for locally recurrent or metastatic progressive RR-DTC
(13,18,19). However, AEs are commonly seen and frequently lead to dose modifications or discontinuations
(20). For this reason, it has been proposed that a lower
starting dose of lenvatinib might result in reduced toxicity in patients with RR-DTC without compromising efficacy. Hence, this study compared, in a double-blinded
fashion, LEN18 with the approved LEN24 in patients with

RR-DTC to see whether the lower starting dose was able
to maintain the same efficacy while conferring less toxicity.
The study did not demonstrate noninferiority of LEN18
compared to the approved LEN24 for RR-DTC (odds ratio
0.5; 95% CI 0.26, 0.96). The 17% difference in ORRwk24
and overall ORR suggests that the LEN24 arm provides a
clinically relevant difference compared to the LEN18 arm.
When baseline characteristic subgroup analyses were conducted, ORRwk24 and overall ORR numerically favored the
LEN24 arm over the LEN18 arm in every group assessed,
with the exception of baseline bodyweight <60 kg (odds
ratio as of week 24: 1.04; 95% CI 0.22, 5.02). Results of
the subgroup analyses should be interpreted with an appropriate level of caution due to small sample sizes and small
numbers of events in each subgroup category. Further, although this analysis was not powered to assess PFS and
the study design included a cutoff leading to censoring for
PFS when the last enrolled patient had their week 24 assessments, PFS for the LEN24 arm was numerically higher
than the LEN18 arm to a clinically relevant magnitude
(Fig. 3). As such, LEN18 did not demonstrate comparable
efficacy to LEN24, and therefore a lower starting dose of
lenvatinib may compromise treatment efficacy.
The primary safety endpoint demonstrated that the incidences of grade ≥3 severity TEAEs up to week 24 were
similar in the LEN24 and LEN18 arms (61.3% vs 57.1%,
respectively; a difference of 4.2%); moreover, the LEN18
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Lenvatinib 24 mg
n = 75

Withdrawal: n = 9
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Table 2. Summary of tumor responses as assessed by investigator using RECIST v1.1
Tumor responses

Lenvatinib starting dose/day
24 mg
(n = 75)

0
0
57.3 (43)
40.3 (31)
36.0 (27)
46.8 (36)
2.7 (2)
5.2 (4)
4.0 (3)
7.8 (6)
57.3 (43) [46.1, 68.5]
40.3 (31) [29.3, 51.2]
−17.1 (−32.7, −1.4)
0.50 (0.26, 0.96)

0
0
64.0 (48)
46.8 (36)
29.3 (22)
40.3 (31)
20.0 (15)
27.3 (21)
2.7 (2)
5.2 (4)
4.0 (3)
7.8 (6)
64.0 (48) [53.1, 74.9]
46.8 (36) [35.6, 57.9]
−17.2 (−32.8, −1.7)
0.50 (0.26, 0.95)
84.0 (63) [75.7, 92.3]
74.0 (57) [64.2, 83.8]
93.3 (70) [87.7, 99.0]
87.0 (67) [79.5, 94.5]
3.7 (2.0, 3.9)
5.8 (3.8, 18.3)
NE (18.4, NE)
20.8 (15.1, NE)

Abbreviations: CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response; RECIST v1.1, Response Evaluation Criteria In Solid
Tumors version 1.1; SD, stable disease.
a
Stable disease is defined as 7 or more weeks after randomization.
b
Durable SD is defined as SD for ≥23 weeks.
c
Among patients who had an objective response: lenvatinib 24-mg arm n = 48, lenvatinib 18-mg arm n = 36.

arm did not have a better safety profile overall. As expected, the median time to first dose reduction in all censored patients was shorter in the LEN24 arm (15.3 weeks)
compared to the LEN18 arm (24.1 weeks). Overall, the
safety profile in this analysis was comparable between arms
and consistent with the known safety profile of lenvatinib
monotherapy (12,21). There were no unexpected toxicities,
and most TEAEs were managed with dose modifications
and supportive therapy.
Although caution should be used in comparing clinical
trials, results from the LEN24 arm of this study are consistent with those from the global Phase 3 SELECT (12). In
SELECT, the ORR as confirmed by independent radiologic
review using RECIST v1.1 was 64.8% in patients who
received LEN24. This rate is similar to the overall ORR
(64.0%), as assessed by investigators using RECIST v1.1,
seen in patients in the LEN24 arm of this study.
Similarly, the safety profiles were comparable between the LEN24 arm in the current study and SELECT.

Specifically, most patients in both studies experienced a
treatment-related AE (LEN24 arm of this study, 98.7%;
SELECT, 97.3%), whereas somewhat fewer experienced a
treatment-related TEAE of grade ≥3 severity in this study
(LEN24 arm, 68.0%; SELECT, 75.9%). Notably, as of week
24 in this analysis in the LEN24 arm, the grade ≥3 TEAE
of hypertension occurred in 25.3% of patients, compared
to the 41.8% incidence of the grade ≥3 treatment-related
AE of hypertension in SELECT. Lenvatinib discontinuations for the primary reason of an AE occurred at similar
rates between the 2 studies (LEN24 arm, 13.3%; SELECT,
14.2%). Additionally, lenvatinib dose reduction rates due
to TEAEs (LEN24 arm, 69.3%; SELECT, 67.8%) were
also comparable between the studies, whereas the rates of
lenvatinib interruption due to TEAEs (LEN24 arm, 64.0%;
SELECT, 82.4%) were somewhat higher within SELECT.
Improvements in treatment-related TEAEs of grade ≥3
severity (especially hypertension) and dose interruption
rates (due to TEAEs) seen in the current study are most
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Week 24
Best overall response, % (n)
  CR
  PR
  SDa
  PD
  Not evaluable
Objective response rate, CR + PR, % (n) [95% CI]
Difference (18 mg − 24 mg), % (95% CI)
Odds ratio (18 mg/24 mg) (95% CI)
Tumor responses, overall
Best overall response, % (n)
  CR
  PR
  SDa
  Durable SDb
  PD
  Not evaluable
Objective response rate (CR + PR), % (n) [95% CI]
   Difference (18 mg − 24 mg), % (95% CI)
   Odds ratio (18 mg/24 mg) (95% CI)
Clinical benefit rate (CR + PR + durable SD), % (n) [95% CI]
Disease control rate (CR + PR + SD), % (n) [95% CI]
Time to first objective response, months, median (95% CI)
Duration of response,c months, median (95% CI)

18 mg
(n = 77)
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(a)
Lenvatinib
24 mg 18 mg
n/n
n/n
31/77

0.50 (0.26–0.96)

57.3

40.3

20/37
11/40

0.80 (0.32–2.01)
0.31 (0.12–0.79)

59.5
55.3

54.1
27.5

17/45
14/32

0.45 (0.19–1.04)
0.59 (0.21–1.63)

57.8
56.7

37.8
43.8

19/37
12/40

0.85 (0.35–2.04)
0.23 (0.08–0.63)

53.7
61.8

51.4
30.0

16/40
4/11
3/5
8/21

0.50 (0.21–1.18)
0.50 (0.09–2.83)
0.57 (0.05–6.05)
0.67 (0.15–3.11)

58.7
54.5
71.4
45.5

40.0
36.4
60.0
38.1

24/52
7/25

0.58 (0.27–1.24)
0.25 (0.05–1.21)

59.0
50.0

46.2
28.0

12/27
12/33
7/17

0.51 (0.13–1.99)
0.52 (0.20–1.39)
0.59 (0.18–1.99)

60.0
55.6
58.3

44.4
36.4
41.2

26/58
5/19

0.69 (0.34–1.41)
0.20 (0.04–0.94)

54.0
75.0

44.8
26.3

30/71
1/2
0/4

0.50 (0.25–0.98)
NE (NE–NE)
NE (NE–NE)

59.4
40.0
0

42.3
50.0
0

6/13
25/64

1.04 (0.22–5.02)
0.46 (0.23–0.93)

50.0
58.2

46.2
39.1

12/35
19/42

0.33 (0.10–1.09)
0.58 (0.25–1.34)

54.5
58.5

34.3
45.2

9/28
22/49

0.50 (0.16–1.59)
0.52 (0.23–1.14)

47.6
61.1

32.1
44.9

0.1

Favors lenvatinib 24 mg

1

10

Favors lenvatinib 18 mg

Odds Ratio and 95% CI

(b)
Lenvatinib
24 mg 18 mg
n/n
n/n
48/75
Overall
Age group
24/37
≤ 65 years
24/38
> 65years
ECOG PS
29/45
0
19/30
1 or 2
Sex
27/41
Male
21/34
Female
Race
29/46
White
6/11
Asian
6/7
Other
7/11
Missing
Previous VEGF
41/61
0
7/14
1
Region
11/15
Europe
23/36
North America
14/24
Other
Histology
38/63
Papillary
10/12
Follicular
Baseline TSH (µIU/mL)
44/69
≤ 0.5
4/5
> 0.5–2.0
0/1
> 2.0–5.5
Baseline weight kg
4/8
< 60 kg
44/67
≥ 60 kg
Prior anticancer radiotherapy
15/22
Yes
No
33/53
Previous anticancer medications
Yes
11/21
No
37/54

Odds Ratio (95% CI) ORR (%)
Lenvatinib
Lenvatinib
18 mg vs 24 mg 24 mg 18 mg

36/77

0.50 (0.26–0.95)

64.0

46.8

21/37
15/40

0.71 (0.28–1.82)
0.35 (0.14–0.87)

64.9
63.2

56.8
37.5

20/45
16/32

0.44 (0.19–1.04)
0.58 (0.21–1.60)

64.4
63.3

44.4
50.0

21/37
15/40

0.62 (0.25–1.58)
0.31 (0.11–0.85)

65.9
61.8

56.8
37.5

19/40
5/11
3/5
9/21

0.54 (0.23–1.30)
0.79 (0.14–4.54)
0.25 (0.02–3.58)
0.36 (0.07–1.92)

63.0
54.5
85.7
63.6

47.5
45.5
60.0
42.9

27/52
9/25

0.50 (0.23–1.10)
0.39 (0.09–1.76)

67.2
50.0

51.9
36.0

12/27
15/33
9/17

0.23 (0.05–1.13)
0.49 (0.18–1.31)
0.95 (0.26–3.39)

73.3
63.9
58.3

44.4
45.5
52.9

29/58
7/19

0.66 (0.32–1.34)
0.17 (0.03–0.90)

60.3
83.3

50.0
36.8

33/71
2/2
1/4

0.49 (0.25–0.98)
NE (NE–NE)
NE (NE–NE)

63.8
80.0
0

46.5
100.0
25.0

7/13
29/64

1.33 (0.25–7.16)
0.43 (0.21–0.88)

50.0
65.7

53.8
45.3

12/35
24/42

0.23 (0.07–0.75)
0.79 (0.34–1.84)

68.2
62.3

34.3
57.1

12/28
24/49

0.64 (0.21–2.02)
0.43 (0.19–0.97)

52.4
68.5

42.9
49.0

0.1

Favors lenvatinib 24 mg

1

10

Favors lenvatinib 18 mg

Odds Ratio and 95% CI
Figure 2. Forest plot of objective response rate by baseline characteristics (investigator assessment per RECIST v1.1) as of week 24 (A) and overall (B).
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not estimable; ORR, objective response rate; RECIST v1.1,
Response Evaluation Criteria In Solid Tumors version 1.1; TSH, thyroid-stimulating hormone; VEGF, vascular endothelial growth factor.
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Overall
43/75
Age group
≤ 65 years
22/37
> 65 years
21/38
ECOG PS
0
26/45
1 or 2
17/30
Sex
Male
22/41
Female
21/34
Race
White
27/46
Asian
6/11
Other
5/7
Missing
5/11
Previous VEGF
0
36/61
1
7/14
Region
Europe
9/15
North America
20/36
Other
14/24
Histology
Papillary
34/63
Follicular
9/12
Baseline TSH (µIU/mL)
≤ 0.5
41/69
> 0.5–2.0
2/5
> 2.0–5.5
0/1
Baseline weight kg
< 60 kg
4/8
≥ 60 kg
39/67
Prior anticancer radiotherapy
Yes
12/22
No
31/53
Previous anticancer medications
10/21
Yes
33/54
No

Odds Ratio (95% CI) ORR (%)
Lenvatinib
Lenvatinib
18 mg vs 24 mg 24 mg 18 mg
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1.0

PFS Probability

0.8
0.6

0.2
0.0

2

4

6

8

10

12
14
16
Time (months)

18

20

22

24

26

28

Number of patients at risk:
Lenvatinib 24 mg
75
63
77
65
Lenvatinib 18 mg

60
56

55
48

46
38

38
32

31
27

18
12

14
7

10
3

4
2

2
0

0
0

0

24
21

20
17

Figure 3. Kaplan-Meier plot of PFS as assessed by investigator using RECIST v1.1. Abbreviations: HR, hazard ratio; NE, not estimable; PFS,
progression-free survival; RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1.

100
Change From Baseline
to Postbaseline Nadir, %

80

n = 72

Lenvatinib 24 mg

60
40
20
0
-20

-30%

-40

-50%

a

-60

-70%

-80

Change From Baseline
to Postbaseline Nadir, %

-100
100
80
60
40
20
0
-20
-40
-60
-80
-100

n = 70

Lenvatinib 18 mg

a

-30%
-50%
-70%

Figure 4. Percentage changes in the sums of diameters of target lesions from baseline to postbaseline nadir (by investigator using RECIST v1.1).
Abbreviation: RECIST v1.1, Response Evaluation Criteria In Solid Tumors version 1.1. aPatients to the right of the arrow achieved at least a 30% reduction of target lesions.

likely because of the increased experience of clinicians with
lenvatinib in the 5 years since its approval and their improved ability to anticipate TEAEs (ie, changes in blood
pressure) and manage toxicity earlier. The double-blinded
nature of this study ensured that physicians were able to
evaluate, grade, and treat the toxicities for patients in both
treatment arms without bias. Moreover, patients were not
biased to the type or severity of toxicities they experienced.
This key aspect of this study deserves to be emphasized

because lack of bias in TEAE assessment adds weight to
the findings.
A limitation of this study is that it was not powered
for PFS or OS because of sample size limitations and because all follow-up ended when the last patient enrolled
had reached week 24. Despite these limitations, a trend
was seen for improved PFS in the LEN24 arm compared
to the LEN18 arm. This study was also limited because
patients generally had good performance status and were
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Median PFS, months (95% CI)
Lenvatinib 24 mg: Not reached (22.1–NE)
Lenvatinib 18 mg: 24.4 (14.7–NE)
HR (95% CI): 1.44 (0.76–2.74)
Log-rank test: P = 0.2648
Censored

0.4

785
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Table 3. Summary of TEAEs
Parameter

Lenvatinib starting dose/day
24 mg
(n = 75)

61.3 (46)

57.1 (44)
−4.2 (−19.8, 11.4)

25.3 (19)
6.7 (5)
2.7 (2)
2.7 (2)
1.3 (1)
2.7 (2)
1.3 (1)
2.7 (2)
2.7 (2)

19.5 (15)
5.2 (4)
5.2 (4)
2.6 (2)
3.9 (3)
2.6 (2)
3.9 (3)
2.6 (2)
2.6 (2)

100 (75)

97.4 (75)

13.3 (10)
65.3 (49)
2.7 (2)
8.0 (6)
76.0 (57)
33.3 (25)
8.0 (6)
30.7 (23)

13.0 (10)
59.7 (46)
7.8 (6)
3.9 (3)
71.4 (55)
40.3 (31)
3.9 (3)
39.0 (30)

14.7 (11)
69.3 (52)
64.0 (48)
82.7 (62)
98.7 (74)
68.0 (51)

16.9 (13)
59.7 (46)
66.2 (51)
80.5 (62)
93.5 (72)
57.1 (44)

9.3 (7)
69.3 (52)
60.0 (45)
80.0 (60)

13.0 (10)
58.4 (45)
55.8 (43)
72.7 (56)

Abbreviation: TEAE, treatment-emergent adverse event.

in better overall health than some patients with RR-DTC
seen in clinical practice. For optimal management, patients
should be monitored closely and frequently after initiation
of treatment.
Additionally, although patients in this study were not
stratified by prior VEGF-targeted therapy and there were
more patients who had received prior VEGF-targeted
therapy in the LEN18 arm (32.5%) compared to the
LEN24 arm (18.7%), a subgroup analysis indicated that
LEN24 may result in improved ORR irrespective of prior
VEGF-targeted treatment, although this did not reach
statistical significance (Fig. 2).

Determining the correct starting dose for cancer treatment is challenging because of the balance between maximizing efficacy while minimizing toxicity. Historically in
oncology, higher dose intensity is thought to be associated
with better outcomes. With development of newer targeted
treatments and immunotherapies where maximum tolerated doses may greatly exceed complete inhibition of biologic targets, it has been suggested that dosing should be
continually evaluated throughout drug development and
that doses lower than the maximum tolerated dose should
be considered (22). Across oncology, use of objective
nonbiased data has been relied on as the cornerstone of
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TEAEs as of week 24
Patients with grade ≥3 severity TEAEs as of week 24, % (n)
Difference [18 mg − 24 mg], % (95% CI)
Most common grade ≥3 TEAEs (≥2%) as of week 24, % (n)
  Hypertension
  Proteinuria
  Asthenia
  Diarrhea
  Hyponatremia
  Increased lipase
  Myalgia
  Stomatitis
  Vomiting
TEAEs overall, % (n)
Patients with any TEAEs
Patients with TEAE worst grade of
  2 (intolerable)
  3
  4
  5
  ≥3
Patients with serious TEAEs
  Fatal
  Nonfatal
Patients with TEAEs leading to
  Dose discontinuation
  Dose reduction
  Dose interruption
   Dose reduction or interruption
Patients with any treatment-related TEAEs
Patients with related TEAEs of grade ≥ 3
Patients with related TEAEs leading to
  Dose discontinuation
  Dose reduction
  Dose interruption
   Dose reduction or interruption

18 mg
(n = 77)
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Table 4. Most common TEAEs (≥25%) overall
Preferred term, % (n)

Lenvatinib starting
dose
18 mg
(n = 77)

57.3 (43)
56.0 (42)
36.0 (27)
40.0 (30)
40.0 (30)
44.0 (33)
38.7 (29)
34.7 (26)
34.7 (26)
21.3 (16)
21.3 (16)

51.9 (40)
51.9 (40)
42.9 (33)
35.1 (27)
35.1 (27)
31.2 (24)
26.0 (20)
28.6 (22)
27.3 (21)
28.6 (22)
28.6 (22)

Abbreviation: TEAE, treatment-emergent adverse event.

Table 5. Dose interruption details
Parameter, % (n)

Number of dose interruptions
1
2
3
≥4
Maximum interruption duration in days
1
2-3
4-7
8-14
15-28
>28

Lenvatinib starting dose/
day
24 mg
(n = 75)

18 mg
(n = 77)

13.3 (10)
16.0 (12)
10.7 (8)
34.7 (26)

24.7 (19)
16.9 (13)
7.8 (6)
24.7 (19)

4.0 (3)
4.0 (3)
10.7 (8)
25.3 (19)
22.7 (17)
8.0 (6)

2.6 (2)
6.5 (5)
15.6 (12)
20.8 (16)
14.3 (11)
14.3 (11)
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Hypertension
Diarrhea
Weight decreased
Fatigue
Nausea
Proteinuria
Arthralgia
Palmar-plantar erythrodysesthesia syndrome
Decreased appetite
Asthenia
Stomatitis

24 mg
(n = 75)

subject to prescriber bias, clear, unbiased data are needed.
Thus, our goal in conducting this study in a randomized,
blinded fashion was to remove both physician and patient
bias from the choice of starting dose of lenvatinib. The results of this study indicate that starting patients at 24 mg/
day, with dose reductions as early and as frequently as necessary, is important for optimizing lenvatinib treatment.
Specifically, the findings from this study support the use of
the approved starting dose of lenvatinib 24 mg/day in patients with RR-DTC, with dose adjustments as tolerated, to
obtain maximum clinical benefit.
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